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Abstract
Introduction This study was performed to determine whether
surfactant application during extracorporeal membrane
oxygenation (ECMO) improves lung volume, pulmonary
mechanics, and chest radiographic findings in children with
respiratory failure or after cardiac surgery.
Methods This was a retrospective chart review study in a
pediatric intensive care unit (PICU). Seven patients received
surfactant before weaning from ECMO was started (group S).
They were compared to six patients treated with ECMO who did
not receive surfactant (group C). These control patients were
matched based on age, weight, and underlying diagnosis.
Demographic data, ventilator settings, tidal volume, compliance
of respiratory system (calculated from tidal volume/(peak
inspiratory pressure – positive end-expiratory pressure), and
ECMO flow were extracted. Chest radiographs were scored by
two blinded and independent radiologists. Changes over time
were compared between groups by repeated-measures
analysis of variance (time*group interaction). Values are given as
percentages of baseline values.
Results The groups did not differ with regard to demographic
data, duration of ECMO, ventilator settings, PICU and hospital
days. After application of surfactant, mean tidal volume almost
doubled in group S (from 100% before to 186.2%; p = 0.0053).
No change was found in group C (100% versus 98.7%). Mean
compliance increased significantly (p = 0.0067) in group S
(from 100% to 176.1%) compared to group C (100% versus
97.6%). Radiographic scores tended to decrease in group S
within 48 h following surfactant application. ECMO flow tended
to decrease in group S within 10 h following surfactant
application but not in group C. Mortality was not affected by
treatment.
Conclusion Surfactant application may be of benefit in children
with respiratory failure treated with ECMO, but these findings
need confirmation from prospective studies.
ARDS = acute respiratory distress syndrome; Crs = compliance of respiratory system; ECMO = extracorporeal membrane oxygenation; PEEP = pos-
itive end-expiratory pressure; PICU = pediatric intensive care unit; PIP = peak inspiratory pressure; RDS = respiratory distress syndrome severity 
score; VT = tidal volume.Critical Care    Vol 9 No 6    Hermon et al.
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Introduction
Extracorporeal membrane oxygenation (ECMO) provides tem-
porary extracorporeal life support for children with severe res-
piratory or cardiac failure. Since 1989, over 27,000 children
have received ECMO with an overall survival rate of 76% [1].
Overall survival for children needing cardiac support is 58%
[1]. ECMO therapy helps to reduce the barotrauma and high-
inspired oxygen concentrations used in conventional mechan-
ical ventilation. During ECMO, patients receive minimal respi-
ratory support while the lungs are bypassed and allowed to
heal. This technology has become safer and more efficient but
complications may still occur, including mechanical complica-
tions in the extracorporeal circuit itself and complications of a
patient's clinical status. The longer the duration of ECMO, the
more complications will occur [2,3].
During the initial course of ECMO, chest radiographs show
diffuse opacification corresponding to variable loss in lung vol-
ume, which leads to decreased lung compliance. When lung
function improves, the lung volume re-expands with a concom-
itant increase in lung compliance and improved aeration as
seen on chest radiographs [4]. The use of exogenous sur-
factant to reduce the duration of ECMO has previously been
recommended by some authors [5,6]. The only reliable indica-
tor so far to determine when to stop ECMO therapy is the
return of adequate pulmonary and/or cardiac function. As oxy-
genation improves, tidal volume (VT) increases and chest radi-
ographs reveal a reduction in pulmonary opacification, and
less ECMO flow is required to maintain adequate arterial and
mixed venous pO2 or saturation.
The objective of the current study was to assess whether sur-
factant application had an impact on VT, compliance of respi-
ratory system (Crs), chest radiographic findings, and ECMO




This study was designed as a retrospective review of all chil-
dren (n = 49) treated with ECMO in our pediatric intensive
care unit (PICU) between 1999 and 2001. ECMO entry crite-
ria at our hospital include: weight greater than 2 kg body
weight, maximal medical therapy consisting of a high fraction
of inspired oxygen, and high pressure settings on the respira-
tor, as well as an oxygenation index greater than 40.
Patients with acute respiratory failure were included, defined
according to the criteria of the American European consensus
conference on acute respiratory distress syndrome (ARDS)
[7]. Patients with congenital heart disease who could not be
weaned from the cardiopulmonary bypass after cardiac sur-
gery were also included in the study.
Medical records of all ECMO patients were reviewed to deter-
mine whether the child received exogenous surfactant after ini-
tiation of ECMO. Seven patients received exogenous
surfactant before starting the weaning procedure from ECMO
(group S). The physician on duty decided on surfactant appli-
cation individually. Of the patients who were treated with
ECMO but did not receive surfactant at any time during their
hospital course, six patients matched on age, weight, and
underlying diagnosis, but not on the basis of 'severity of dis-
ease', were chosen as controls (group C). Patients' medical
records were reviewed for the following information: demo-
graphic data, ventilator settings (peak inspiratory pressure
Table 1
Demographic and clinical data of extracorporeal membrane oxygenation patients (n = 49) between 1999 and 2001
Group S (surfactant; n = 7) Group C (control; n = 6) Remaining ECMO patients (n = 
36)
Gender (male/female) 5/2 6/0 25/11
Age (months)a 5.1 ± 8.5 7.5 ± 9.7 11 ± 25.1
Weight (kg)a 5.1 ± 3.5 6.0 ± 4.1 6.3 ± 7.3
Diagnosis (ARDS/CHD)a 5/2 (71%/29%) 4/2 (67%/33%) 8/19 (22%/53%)
ECMO (days) 9 ± 7.9 9 ± 6.2 6.7 ± 4.9
ECMO (hours) 217.4 ± 198 214.8 ± 152 154.2 ± 117.2
PICU (days) 24.5 ± 19.2 19.5 ± 4.3 18.3 ± 14.1
Ventilator (days) 23.5 ± 17.7 17.5 ± 5.1 16.2 ± 13.4
Hospital (days) 29.5 ± 18.3 23.2 ± 8.8 22.3 ± 16
Survival (y/n) 2/5 3/3 16/20 (44%/56%)
aMatching variables. Data are presented as mean ± standard error of the mean. There were no significant differences between the two groups 
regarding all demographic data. ARDS, acute respiratory distress syndrome; CHD, congenital heart disease; ECMO, extracorporeal membrane 
oxygenation; PICU, pediatric intensive care unit.Available online http://ccforum.com/content/9/6/R718
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(PIP), positive end-expiratory pressure (PEEP), fraction of
inspired oxygen (FiO2), respiratory rate, VT), and ECMO flow.
Crs was estimated by the ratio VT/(PIP – PEEP) from a single
expiratory tidal volume. This was performed without discon-
necting the patient from the ventilator, the only limitation being
that a single VT and pressure difference was used to calculate
compliance. The time points for this information determined for
group S patients were: before surfactant application (base-
line); and 4 h and 10 h after surfactant application. Time points
for group C patients were: baseline (mid-time of ECMO
course) and 4 h and 10 h after baseline. These time points
were chosen to roughly correspond to the course in group S
patients, who received their surfactant approximately at the
mid-time of the ECMO course.
Chest radiographs were evaluated by two independent pedi-
atric radiologists blinded to treatment groups. The respiratory
distress syndrome severity scoring system devised by
Edwards et al. [8] with a score range from 4 to 20 was used.
This score evaluates the following criteria: degree of aeration
and pulmonary opacification, presence of air bronchograms,
and cardiac and diaphragmatic silhouette definition.
Chest radiographs for group S were obtained before sur-
factant application (baseline), 24 and 48 h thereafter, and for
group C at baseline (mid-time of the ECMO course), and 24
and 48 h thereafter.
Children in group S received 50 to 80 mg/kg body weight por-
cine surfactant (Curosurf®, Chiesi, Italy) as an intratracheal
bolus. The children were handbag ventilated during surfactant
application with 100% oxygen using peak pressures and res-
piratory rates that approximated previous ventilator settings on
ECMO. The whole application procedure lasted about 2 min-
utes. Endotracheal suctioning was not performed within 4 h
after surfactant application.
All patients were ventilated with a time cycled, pressure con-
trolled ventilator (Babylog 8000, Dräger, Lübeck, Germany).
Hemodynamic variables were monitored online by using a
pressure transducer and ECG electrodes and displayed on a
monitor system (Hewlett-Packard, Model 68 S, Palo Alto, CA,
USA). All patients were treated with midazolam and fentanyl
analgesia and received pancuronium bromide for relaxation.
Veno-arterial ECMO was initiated using neck cannulation in
two children and through median sternotomy in four children.
In these latter children, the sternum was left open with primary
skin closure. For veno-venous ECMO (n = 7), we used right
internal jugular vein and right femoral vein access. The heparin-
coated ECMO circuit consisted of a Biomedicus BP 50 cen-
trifugal pump head (Medtronic Inc., Anaheim, CA, USA) and a
Quadrox D (Jostra, Hirrlingen, Germany) oxygenator.
Statistical analysis
Statistical analysis was performed with commercially available
computer software packages (Minitab version 13.1(Minitab
Figure 1
Tidal volumes (VT) of the surfactant group (group S) and control group (group C) Tidal volumes (VT) of the surfactant group (group S) and control group (group C). The X-axis represents the time points before (baseline) and 4 and 
10 h after surfactant application for group S. For group C, the time points are baseline (mid-time of the ECMO course) and 4 and 10 h thereafter. 
The Y-axis represents values of VT as percentages of baseline values. VT showed a significant increase over time in group S compared to group C 
(repeated-measures, analysis of variance, group*time interaction, p = 0.0053).Critical Care    Vol 9 No 6    Hermon et al.
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Inc., Lebanon, PA, USA), SAS/STAT, version 8.2 (SAS Insti-
tute Inc., Cary, NC, USA)). Demographic variables were com-
pared between groups using Wilcoxon sign rank test or
Fisher's exact test. For outcome variables (VT, Crs, respiratory
distress syndrome severity score (RDS), ECMO flow), base-
line differences between groups were assessed using Stu-
dent's  t test. Changes over time were compared between
groups by repeated-measures analysis of variance
(time*group interaction). Values are given as percentage of
baseline values. All tests were two-sided. Significance for all
comparisons was accepted at p < 0.05.
The study was exempted from review by the Ethics Committee
of the Medical University of Vienna and from the requirement
for informed consent because it involved the examination of
existing data and documents.
Results
Between 1999 and 2001, 857 children were admitted at our
PICU. Of these children, 49 were treated with ECMO (5.8%
of all admitted children): 17 children (35% of all ECMO
patients) had ARDS, 23 children (46%) had congenital heart
disease, and 9 children (18%) had another diagnosis. Seven
children were treated with surfactant during ECMO (group S;
14% of all ECMO patients). Six children who did not receive
surfactant were matched as a control group (group C). Demo-
graphic data of both groups are listed in Table 1. Groups were
matched based on age, weight, and underlying diagnosis.
There were no significant differences between the two groups
regarding all demographic data. The most common diagnosis
in both groups was ARDS. Comparison of the two groups for
duration of ECMO, PICU, ventilator and hospital days revealed
no significant differences.
The measured variables VT, Crs and RDS showed moderate
differences between groups at baseline (p values not signifi-
cant). Independent of baseline differences, however, these
variables showed significant changes over time as assessed
by repeated measures analysis of variance. All values are given
as changes in percentage of baseline values. Mean VT
improved significantly over time in group S (100% at baseline
versus 186.2% at 10 h after surfactant application) compared
to group C (100% versus 98.7%; p = 0.0053) (Figure 1). Sim-
ilarly, mean Crs values increased significantly over time in
group S (100% before versus 176.1% at 10 h after surfactant
application) compared to group C (100% versus 97.6%; p =
0.0067) (Figure 2).
Radiographic scores are shown in Figure 3. Mean RDS values
of group S improved moderately (100% at baseline versus
61.1% at 48 h after surfactant application). In group C, mean
RDS values did not change within 24 h, but then increased to
132%, evidence of a mild aggravation (p = 0.14). Mean
ECMO flow (l/minute) decreased over time in group S (100%
at baseline versus 76.6% at 10 h after surfactant application).
In group C, ECMO flow did not change over the measured
time points (100% versus 100.03%, p = 0.18) (Figure 4). Sur-
vival in group S was 29% and in group C 50% (p = 0.59).
Figure 2
Compliance of respiratory system (Crs) calculated from the ratio tidal volume/(peak inspiratory pressure – positive end expiratory pressure) for the  surfactant group (group S) and control group (group C) Compliance of respiratory system (Crs) calculated from the ratio tidal volume/(peak inspiratory pressure – positive end-expiratory pressure) for the 
surfactant group (group S) and control group (group C). The X-axis represents the time points before (baseline) and 4 and 10 h after surfactant 
application for group S. For group C, the time points are baseline (mid-time of the ECMO course) and 4 and 10 h thereafter. The Y-axis represents 
values of Crs as percentages of baseline values. Crs showed a significant increase over time in group S compared to group C (repeated-measures, 
analysis of variance, group*time interaction, p = 0.0067)Available online http://ccforum.com/content/9/6/R718
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Discussion
We found that surfactant application in children with respira-
tory failure treated with ECMO was associated with improved
lung volume and pulmonary mechanics within 10 h. Tidal vol-
ume and Crs improved significantly in the surfactant group
compared to the control group over the course of time. In addi-
tion, chest radiograph scores showed a trend to improvement
in the surfactant group but not in the control group. Moreover,
ECMO flow tended to decrease 10 h after surfactant
application. However, there was no significant difference in
overall outcome.
To our knowledge there have been only few previous studies
describing surfactant therapy during ECMO [5,6]. These stud-
ies reported on term neonates, however, and not on infants
and children as in our present study. This study was performed
as a retrospective case control study. The decision for treat-
ment with surfactant during ECMO was made by the physician
o n  d u t y  o n  a n  i n d i v i d u a l  b a s i s .  P a t i e n t s  o f  g r o u p  C  w e r e
matched based on age, weight and underlying diagnosis, but
not according to the severity of disease. This explains why
baseline values differed between the two groups, but not sig-
nificantly. However, changes over time expressed as percent-
age of baseline values showed significant differences
between both groups.
ECMO remains a useful technique in the management of chil-
dren with respiratory failure. The optimal timing for placing chil-
dren on ECMO is still difficult to determine. Greenspan et al.
[9] suggested that delaying ECMO therapy might increase the
risk of lung injury, particularly to the airway. New treatment
strategies and ventilator techniques for respiratory failure were
introduced in the past decade with the implication of fewer
requirements for ECMO. These new treatment strategies,
such as inhaled nitric oxide, high frequency ventilation and sur-
factant replacement, may be used as co-therapy with ECMO
in order to shorten ECMO runs and thereby reduce complica-
tions with ECMO [3].
Multiple causes of surfactant deficiency exist in children
requiring ECMO, making surfactant replacement a treatment
option. Hyperventilation and hyperoxia, often required for the
patient with severe respiratory failure and persistent pulmo-
nary hypertension, can lead to barotraumas and oxygen toxicity
[10]. Surfactant function and pulmonary mechanics are
impaired by the influx of protein-rich fluid and blood into the
alveolar space [11-13]. Pulmonary edema is usually present
for the first 48 to 72 h after initiation of ECMO as assessed by
chest radiographs [13]. Prevention of this initial course may be
clinically important to reduce ECMO duration and to avoid
high ventilation requirements during the weaning period from
ECMO therapy and after removing the patient from bypass.
Some investigators have previously reported improved pulmo-
nary mechanics and decreased duration of ECMO in neonates
who had received multiple doses of surfactant while on extra-
corporeal bypass [5,6]. Our patients were infants and children
(mean age of 6 months) and received only one dose of sur-
factant. The average duration of ECMO in neonates is 120 h
[14]. Our patients in both groups remained on ECMO approx-
imately 215 h. We agree with Green and coworkers [14] who
argued that for the special case of veno-arterial ECMO, it
Figure 3
Respiratory distress syndrome severity score (RDS) for the surfactant group (group S) and control group (group C) Respiratory distress syndrome severity score (RDS) for the surfactant group (group S) and control group (group C). The X-axis represents time 
points when radiographs were obtained and scored (baseline (before surfactant application) and 24 and 48 h thereafter) for group S, and for group 
C at baseline (mid-time of ECMO-course) and 24 and 48 h thereafter. The Y-axis represents the radiographic RDS score.Critical Care    Vol 9 No 6    Hermon et al.
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seems unlikely that ECMO has any direct therapeutic effect in
acute lung-injured patients separate from its support of gas
exchange. Therefore, the duration of ECMO must be long
enough to allow substantial lung repair to occur. The duration
of ECMO correlates with measurable indicators of severe pul-
monary disease, such as PIP and prolonged mechanical venti-
lation before ECMO.
ECMO is reserved in most centers only for patients for whom
the likelihood of survival with the continuation of conventional
therapy appears remote. In that respect, the overall survival of
our patients (mean of both groups 40%) appears
encouraging.
The assessment of VT and Crs may offer the clinician a possi-
bility of a more objective evaluation of pulmonary status and
the recovery from lung injury compared with the conventional
assessment by chest radiographs and blood gases [15].
Chest radiograph findings lag behind the clinical and physio-
logical recovery of the lung. Blood gases during ECMO mainly
reflect gas exchange in the membrane lung (Oxygenator) of
the ECMO circuit and only in a small amount reflect gas
exchange in a patient's lungs. Compliance increased signifi-
cantly in the surfactant group after surfactant application, indi-
cating alveolar recruitment of the lung as pressure difference
(PIP – PEEP levels) was almost unchanged over the different
time points measured. Reiterer et al. [16] and previous inves-
tigators [5,17-20] have described improvement of compliance
during ECMO and especially in combination with surfactant
treatment. They mentioned that Crs, functional residual capac-
ity and VT improved significantly, and each of these parame-
ters correlated with successful weaning from ECMO. The
combination of functional residual capacity and Crs was the
best predictor for successful weaning from ECMO [17]. The
decision of when to stop ECMO is based upon the return of
adequate pulmonary and cardiac function to support vital
organs and permit subsequent recovery [21].
Conclusion
We found that surfactant replacement during ECMO in chil-
dren with respiratory failure improved lung volume; pulmonary
mechanics and measurement of these parameters may assist
weaning from ECMO. ECMO reduces the need for high levels
of respiratory support and it might be reasonable not to delay
the initiation of it. The central question whether surfactant
application during ECMO may improve outcome also in terms
of higher survival has to be investigated in prospective control-
led clinical trials.
Figure 4
ECMO flow for the surfactant group (group S) and control group (group C) ECMO flow for the surfactant group (group S) and control group (group C). The X-axis represents the time points before (baseline) and 4 and 10 h 
after surfactant application for group S. For group C, the time points are baseline (mid-time of the ECMO course) and 4 and 10 h thereafter. The Y-
axis represents ECMO flow as percentages of baseline values.
Key messages
•  ECMO provides temporary life support for children with 
severe respiratory or cardiac failure. Although ECMO 
has become safer and more efficient, complications are 
still a threat.
•  Surfactant replacement during ECMO in children with 
respiratory failure improved lung mechanics and sup-
ported tolerance to and assisted weaning from ECMO.Available online http://ccforum.com/content/9/6/R718
R724
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